

ALEXEY TARASOV

*Admitted to U.S. Supreme Court,
Courts of Appeals for the
Second, Fourth, Fifth, Seventh,
Eighth, Ninth & Tenth Circuits,
Southern District of Texas,
District of Columbia,
Southern & Eastern
Districts of New York,
Western District of Oklahoma*

attorney and counselor at law

5211 Reading Road
Rosenberg, Texas 77471

330 W. Gray Street, suite 208
Norman, Oklahoma 73069

*licensed in Texas,
Oklahoma, New York*

telephone: 832.623.6250
fax: 832.558.3540
alexey@tarasovlaw.com

May 10, 2025

Via Electronic Transmission

OTC Markets Group Inc.
300 Vesey Street, 12th Floor
New York, NY 10282

Subject: Correspondence Regarding Current Information – RAFA

Dear Sir/Madam:

I have been engaged by Rafarma Pharmaceuticals, Inc. (“RAFA”), a Wyoming Corporation, whose primary office is located at 12465 South Street STE 240, Draper, UT 84020 (hereinafter referred to as the “Issuer”), specifically to provide this letter. Only OTC Markets Group is authorized to rely on this letter and use it to determine if adequate current information has been made publicly available on its website, as per Rule 144(c)(2) of the Securities Act of 1933. OTC Markets Group is granted unrestricted permission and rights to publish this letter through the OTC Disclosure & News Service for public access.

I am a U.S. resident and hold licenses to practice law in Texas, Oklahoma, and New York. I have not been suspended or barred from practicing law in any state or jurisdiction, including the Securities and Exchange Commission (“SEC”), nor have I faced any civil or criminal charges. My role as independent counsel is solely to review the current information provided by the issuer. I do not possess any beneficial ownership in the Issuer’s securities. I have not received, nor do I have an agreement to receive in the future, shares of the Issuer’s stock as payment for services.

To prepare this letter, I have reviewed pertinent corporate records and other documents, as well as addressed any legal questions I deemed necessary or relevant. The documents I have examined (“Information”) encompass, but are not limited to:

OTC Publish Date	OTC Disclosures Title	Period End Date
04/07/2025	Annual Report – Annual Report – RAFA Report 2024	12/31/2024
12/16/2024	Quarterly Report – Combined fin. statement Rafarma 30 Sept 2024 – Amended – Q3	09/30/2024
09/17/2024	Quarterly Report – RAFA statement 2Q 2024	06/30/2024
08/14/2024	Quarterly Report – 2Q2024	06/30/2024
05/15/2024	Quarterly Report – 1Q2024	03/31/2024

In regard to factual matters, I have depended on information gathered from public officials, officers, and directors of the Issuer, and other sources, which are considered trustworthy. When examining the Information, I have assumed that:

1. All statements and representations within the Information were accurate and reliable;
2. All signatures within were authentic;
3. All documents provided to me were true copies; and
4. All individuals who signed documents possessed the legal capacity to do so.


Upon conducting the aforementioned review and considering other matters detailed herein, I am of the opinion that the Information (i) represents “adequate current public information” about the Securities and the Issuer; (ii) has been made publicly accessible as per Rule 144(c)(2) under the Securities Act; (iii) contains all information a broker-dealer would need to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 of the Securities Exchange Act of 1934 (the “Exchange Act”); (iv) adheres to the form requirements of the OTC Markets Group’s Pink Basic Disclosure Guidelines; and (v) has been submitted through the OTC Disclosure & News Service.

Raivo Unt, the President, who I have communicated with, was responsible for preparing the Disclosure Statement included in the Information. The Issuer’s transfer agent is Securities Transfer Corporation, which is registered with the Securities and Exchange Commission. I relied on information provided by Action Stock Transfer to verify the number of outstanding shares mentioned in the Information.

To the best of my knowledge, after inquiring with the Issuer’s management and directors, neither the Issuer, any 5% holder, nor counsel, is presently under investigation by any federal or state regulatory authority for violations of federal or state securities laws.

The Issuer is not classified and, to the undersigned’s knowledge, has never been classified as a “shell company” according to Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. No party other than the OTC Markets Group may rely on this letter; however, the OTC Markets Group has unrestricted permission and rights to publish the letter through the OTC Disclosure & News Service for public access. This letter pertains solely to the referenced report periods and is not applicable to any other period.

Respectfully,



Alexey V. Tarasov, Esq.